Literature DB >> 19581665

Hypomagnesaemia due to use of proton pump inhibitors--a review.

M T Kuipers1, H D Thang, A B Arntzenius.   

Abstract

Magnesium homeostasis is essential for many intracellular processes and depends on the balance of intestinal absorption and renal excretion. Hypomagnesaemia may arise from various disorders. We review the literature on hypomagnesaemia due to the use of proton pump inhibitors, as illustrated by a case of a 76-year-old woman with muscle cramps and lethargy caused by hypomagnesaemia and hypocalcaemia with a low parathyroid hormone level while using esomeprazole, a proton pump inhibitor (PPI). After oral magnesium repletion both abnormalities resolved. Fractional magnesium excretion was low, excluding excessive renal loss. A causal relation with PPI use was supported by the recurrence of hypomagnesaemia after rechallenge. In the past decade our understanding of transcellular magnesium transport was enhanced by the discovery of several gene mutations i.e. transient receptor potential melastin (TR PM) 6 and 7. In this light we discuss the possible aetiology of proton pump inhibitor related hypomagnesaemia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19581665

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  36 in total

1.  Proton pump inhibitor associated hypomagnasaemia - a cause for concern?

Authors:  Joe Begley; Trevor Smith; Kirsty Barnett; Paul Strike; Adnan Azim; Claire Spake; Tristan Richardson
Journal:  Br J Clin Pharmacol       Date:  2016-01-25       Impact factor: 4.335

2.  Proton pump inhibitors use in hemodialysis patients and serum magnesium levels.

Authors:  Emre Erdem
Journal:  Int J Clin Exp Med       Date:  2015-11-15

3.  Proton pump inhibitor-induced hypomagnesemia: A new challenge.

Authors:  Matilda Florentin; Moses S Elisaf
Journal:  World J Nephrol       Date:  2012-12-06

Review 4.  A benefit-risk assessment of the use of proton pump inhibitors in the elderly.

Authors:  Gwen M C Masclee; Miriam C J M Sturkenboom; Ernst J Kuipers
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

5.  Proton-pump inhibitors do not influence serum magnesium levels in renal transplant recipients.

Authors:  Charlotte Van Ende; Steven Van Laecke; Celine Marechal; Francis Verbeke; Nada Kanaan; Eric Goffin; Raymond Vanholder; Michel Jadoul
Journal:  J Nephrol       Date:  2014-05-10       Impact factor: 3.902

6.  Proton-pump inhibitor use is associated with lower urinary magnesium excretion.

Authors:  Jeffrey H William; Rachel Nelson; Najwah Hayman; Kenneth J Mukamal; John Danziger
Journal:  Nephrology (Carlton)       Date:  2014-12       Impact factor: 2.506

Review 7.  Proton-pump inhibitor-induced hypomagnesemia: Current research and proposed mechanisms.

Authors:  Jeffrey H William; John Danziger
Journal:  World J Nephrol       Date:  2016-03-06

8.  Local protective effects of oral 45S5 bioactive glass on gastric ulcers in experimental animals.

Authors:  Ai-niu Ma; Nian Gong; Jin-miao Lu; Jin-lu Huang; Bin Hao; Yang Guo; Jipin Zhong; Yuhong Xu; Jiang Chang; Yong-xiang Wang
Journal:  J Mater Sci Mater Med       Date:  2013-01-18       Impact factor: 3.896

9.  Proton-pump inhibitor use is associated with low serum magnesium concentrations.

Authors:  John Danziger; Jeffrey H William; Daniel J Scott; Joon Lee; Li-wei Lehman; Roger G Mark; Michael D Howell; Leo A Celi; Kenneth J Mukamal
Journal:  Kidney Int       Date:  2013-01-16       Impact factor: 10.612

10.  Long-term proton pump inhibitor use is associated with vascular calcification in chronic kidney disease: a cross-sectional study using propensity score analysis.

Authors:  Maria Fusaro; Marianna Noale; Giovanni Tripepi; Sandro Giannini; Angela D'Angelo; Angelo Pica; Lorenzo A Calò; Davide Miozzo; Maurizio Gallieni
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.